ak154 + cadonilimab

AK154 + cadonilimab is a combination therapy comprised of **AK154** and **cadonilimab**. Cadonilimab is a tetravalent bispecific monoclonal antibody that targets **programmed cell death protein 1 (PD-1)** and **cytotoxic T-lymphocyte associated protein 4 (CTLA-4)** to enhance T-cell mediated anti-tumor activity. Its Fc-null design reduces Fc-mediated toxicities and improves binding selectively in the tumor microenvironment. Cadonilimab is developed by Akeso for cancer immunotherapy, particularly as a checkpoint inhibitor in various solid tumors including hepatocellular carcinoma and gastric/GEJ adenocarcinoma[2][5]. **AK154** is not described in the search results and its identity, mechanism, or target is unknown; thus, the combination is treated as a multi-agent investigational oncology therapy. Cadonilimab is typically administered intravenously and is being studied as part of several clinical trials in combination strategies, often with chemotherapy or other targeted therapies[2][6].

Other names

ak154ak-154ak 154cadonilimabak104ak-104ak 104